Share Twitter LinkedIn Facebook Email Andrew Pecora, MD Chief Innovation Officer, Professor and Vice President of Cancer Services, John Theurer Cancer Center, discusses Results Of The CPIT Trial. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Inotuzumab Ozogamicin and Gemtuzumab Ozogamicin: A 2024 Guide to Managing Liver Toxicity and Cancer Treatment for Oncologists [40 Slides] Hematologic Malignancies 5 Mins Read
Non-Malignant Hematology Clinics: Essential Pioneers in the Evolving Hematologic Care Hematologic Malignancies 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read